MLXIPL and fatty liver disease: To test its potential oncogenic function, ChREBP was specifically overexpressed in the liver of male C57BL6/J mice. Three weeks after adenoviral ChREBP delivery, mice displayed hepatic steatosis, that was characterized by increased liver weight and size (Fig. 2a).